Together, these experiments indicate that de novo established aggressive glioma tumors expressing IL13RA2 are responsive to CAR T-cell therapy, and thus, are suitable for investigating responses and resistance of aggressive pediatric diffuse gliomas to targeted therapeutics in mice with fully competent immune system. The gene discussed is IL13RA2; the disease is central nervous system cancer.